

Microbes and Infectious Diseases

Journal homepage: https://mid.journals.ekb.eg/

Letter to the Editor

COVID-19 mutation in the United Kingdom

Siukan Law^{1*}, Albert Wingnang Leung², Chuanshan Xu³

1- Department of Science, School of Science and Technology, The Open University of Hong Kong, Ho Man Tin, Kowloon, Hong Kong,

School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong.
Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & Fifth

Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.

LETTER INFO

Letter history: Received 17 December 2020 Received in revised form 18 January 2021 Accepted 27 January 2020

Keywords:

COVID-19 Mutation United Kingdom

Dear Editor

On the 23rd of December 2020, the United Kingdom discovered a new mutation strain from SARS-CoV-2 known as VUI-202012/01 [1]. The viruses seem to be mutated all the time and their behavior and properties were changed relating to a lot of uncertainties including the effects of environmental and human-to-human interaction. What did we concern about this variant? That was the speed of its virus transmission for humans.

Based on a case confirmed in Northern Ireland that the rate of transmissible for this variant was higher than 70%. According to the modeling studied by Prime Minister Boris Johnson, the ability to spread its virus could increase to 0.4 probability but there was no evidence to prove the new mutation strain would cause a higher mortality rate. **Rambaut et al.** reported that a novel set of spike mutation strains in SARS-CoV-2 regarding the B.1.1.7 lineage accounts for an increasing proportion of cases in the United Kingdom. They identified the N501Y gene mutation within the receptor-binding domain (RBD). The spike deletion 69-70 del increased the binding affinity of angiotensin-converting enzyme 2 (ACE2) and changed the receptor-binding domain (RBD) associated with the human immune system [2]. Would the vaccine still suitable for its mutation strain?

Up to the present, there is no reason to support the effectiveness of a COVID-19 vaccination would be influenced after mutation, such as SARS-CoV-2 increase its virulence or cross change in the spike protein. Vaccine function is to initiate an immune system. It produces antibodies for combating the SARS-CoV-2. This prevents the spike proteins interaction with an angiotensin-converting enzyme 2 (ACE2) specific receptor on the alveolar cell surface in the lung [3].

How does the United Kingdom stop the spread of SARS-CoV-2 and its mutation? SARS-CoV-2 spread by self-replicating within a host organism and mutates after the attack on the human immune system to get an evolution. If no replication of the virus so no mutation. Public and personal health are the most important things to contain the pandemic including keeping a social distance, wearing a face mask, washing hands frequently, and ban group gathering. The

DOI: 10.21608/MID.2021.57042.1109

^{*} Corresponding author: Siukan Law

E-mail address: siukanlaw@hotmail.com

^{© 2020} The author (s). Published by Zagazig University. This is an open access article under the CC BY 4 license https://creativecommons.org/licenses/by/4.0/.

Government of the United Kingdom has implemented six key health protection regulations such as back from another country (international travel), stay at home, wearing of face coverings in a relevant place, collection of people infected or closed contact people details, self-isolation, and local authority enforcement powers to reduce the transmission and spread of SARS-CoV-2 [4]. Certainly, vaccine development and its vaccination, is the best way for the COVID-19 pandemic situation.

Author contributions

All authors contributed to the concept, acquisition and analysis of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Conflicts of interest

The authors have no conflicts of interest to disclose.

Funding/support

The authors received no funding source/grants or other materials support for this work.

References

1-Mee E, Hayes A. COVID-19: New mutation now in every part of UK - here's what we know, 2020. Available at:

https://news.sky.com/story/covid-19-should-

we-be-worried-about-the-new-coronavirus-

mutation-12161566. Accessed Dec 28, 2020.

- 2-Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. nCoV-2019 Genomic Epidemiology 2020.
- 3- Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies [published online ahead of print, 2020 Nov 25]. Eur J Pharmacol 2020; 892: 173751.

4-**The Government of the United Kingdom.** Coronavirus Legislation (UK). 21 Dec 2020. Available at:

https://www.legislation.gov.uk/coronavirus.

Accessed Dec 28, 2020.